Cancer

News

FDA advisors reject one Daiichi Sankyo cancer drug, back ano...

Daiichi Sankyo had a day of mixed fortunes after advisers to the US regulator voted against approval for its leukaemia drug quizartinib, but recommended pexidartinib for a rare tumour.

News

Lilly gets fifth use for Cyramza with FDA liver cancer nod

Eli Lilly’s Cyramza has a new string to its bow after the FDA approved it as a second-line treatment for certain liver cancer patients, and received a further boost as the FDA removed a box

News

AZ and Daiichi to file new breast cancer drug after trial su...

In March AstraZeneca asked investors for $3.5 billion to fund a collaboration with Daiichi Sankyo over a new breast cancer drug – and it looks like the project is on track.

News

NICE recommends Roche's Tecentriq combo for certain lung can...

Certain patients with untreated lung cancer in England have a new treatment option after cost-effectiveness body NICE made a draft recommendation that the NHS should fund Roche’s cocktail i

News

Keytruda drives another strong Merck quarter, but what’s nex...

Merck & Co/MSD’s first quarter followed the predictable pattern of a surge in sales on the back of immuno-oncology blockbuster Keytruda, but analysts are starting to ask how the company

News